R. Ciftciler Et Al. , "Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients," HEMATOLOGY REPORTS , vol.12, no.1, 2020
Ciftciler, R. Et Al. 2020. Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. HEMATOLOGY REPORTS , vol.12, no.1 .
Ciftciler, R., GÖKER, H., BÜYÜKAŞIK, Y., SAYINALP, N., HAZNEDAROĞLU, İ. C., AKSU, S., ... Ozcebe, O.(2020). Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients. HEMATOLOGY REPORTS , vol.12, no.1.
Ciftciler, Rafiye Et Al. "Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients," HEMATOLOGY REPORTS , vol.12, no.1, 2020
Ciftciler, Rafiye Et Al. "Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients." HEMATOLOGY REPORTS , vol.12, no.1, 2020
Ciftciler, R. Et Al. (2020) . "Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients." HEMATOLOGY REPORTS , vol.12, no.1.
@article{article, author={Rafiye Ciftciler Et Al. }, title={Comparison of bortezomib-cyclophosphamide-dexametha-sone versus bortezomib-dexamethasone based regimens in newly diagnosed multiple myeloma patients}, journal={HEMATOLOGY REPORTS}, year=2020}